Design, synthesis, and anti-integrase activity of catechol–DKA hybrids Original Research Article

Following the discovery of diketoacid-containing compounds as HIV-1 integrase (IN) inhibitors, a plethora of new molecules have been published leading to four drugs under clinical trial. In an attempt to rationally design new dimeric diketoacids (DKAs) targeting two divalent metal ions on the active site of IN, potent inhibitors against purified IN were found with varied selectivity for strand transfer. In this context, we designed and synthesized a new series of catechol–DKA hybrids. These compounds presented micromolar anti-integrase activities with moderate antiviral properties.